Telix Pharmaceuticals Limited — Company profile
Healthcare · Biotechnology · Australia
Last price 9.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Details
| Name | Telix Pharmaceuticals Limited |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 1184 |
| Founded | 2015 |
| Ceo | Christian Behrenbruch |
| Country | Australia |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US87961M1053 |
| Cusip | 87961M105 |
| Cik | 2007191 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D | Co-Founder, MD, Group Chief Executive Officer and Executive Director |
| Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer |
| Darren Patti Pharm.D. | Group Chief Operating Officer |
| Dr. David N. Cade M.B.A., M.D., MBBS | Group Chief Medical Officer |
| Dr. Paul Schaffer | SVice President of Research and Development |
| Craig Ulrick | Chief Information Officer |
| Kyahn Williamson B.A. | Senior Vice President of Corporate Communications and Investor Relations |
| Christian Krautkramer J.D. | Group General Counsel |
| Thomas Fromm | Senior Vice President of Sales |
| Meredith Crowe BDES | Senior Vice President of Global People and Culture |
Contact
| Address | 55 Flemington Road, Level 4, North Melbourne, VIC 3051, Australia |
| Phone | 61 3 9093 3855 |
| Website | https://telixpharma.com |